

28 October 2020

Change in Director's Interest Notice x 2

PYC Therapeutics Limited (the 'Company') submits the following Appendix 3Y's – Change in Director's Interests, in relation to Alan Tribe and Bernard Hockings, from participation in the accelerated component of the non-renounceable entitlements issue.

This ASX announcement was approved and authorised for release by the Rohan Hockings CEO of PYC Therapeutics Limited.

ENDS For further information, please contact:

INVESTORS

Rohan Hockings
CEO
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics Limited

ACN 098 391 961

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|---------------------------------|
| Name of entity | PYC THERAPEUTICS LIMITED |
| ABN | 48 098 391 961 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|---------------------------|
| Name of Director | Alan William Tribe |
| Date of last notice | 15 June 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | INDIRECT |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Mr Tribe is a Director of Australian Land Pty Ltd, Delarge Investments Pty Ltd, Runcion Pty Ltd, Pagham Pty Ltd and Stockbridge Corporation Pty Ltd. |
| Date of change | 28 October 2020 |
| No. of securities held prior to change | 882,563,760 ordinary shares |
| Class | Ordinary shares |
| Number acquired | 88,256,376 ordinary shares |
| Number disposed | Nil |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | \$0.17 per ordinary share |
| No. of securities held after change | 970,820,136 ordinary shares |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|--|
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Participation in accelerated component of non-renounceable entitlements issue. |
|---|--|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|---------------------------------|
| Name of entity | PYC THERAPEUTICS LIMITED |
| ABN | 48 098 391 961 |

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|--|
| Name of Director | Bernard Edward Frederick Hockings |
| Date of last notice | 15 June 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | INDIRECT Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings Private S/F 2 A/C) |
| Date of change | 28 October 2020 |
| No. of securities held prior to change | DIRECT - 103,351,783 Ordinary Shares INDIRECT - Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings private S/F 2 A/C) 156,542,436 Ordinary shares - Alexandra Hockings (Daughter) 2,708,172 Ordinary shares - James Hockings (Son) - 1,057,180 Ordinary shares |
| Class | Ordinary shares |
| Number acquired | 2,941,177 |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Participation in accelerated component of non-renounceable entitlement issue. |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|--|--|
| Number disposed | nil |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | \$0.17 per share |
| No. of securities held after change | DIRECT <ul style="list-style-type: none"> - 105,392,960 Ordinary Shares INDIRECT <ul style="list-style-type: none"> - Dr Bernard Edward Hockings & Mrs Dianne Christine Hockings (B Hockings private S/F 2 A/C) 157,442,436 Ordinary shares - Alexandra Hockings (Daughter) 2,708,172 Ordinary shares - James Hockings (Son) 1,057,180 Ordinary shares |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

⁺ See chapter 19 for defined terms.